Mexico Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2026-2034

June 2026 | 115 pages | ID: MB4AED614CA2EN
IMARC Group

Abstracts

The Mexico pharmacovigilance market size reached USD 137.2 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 263.1 Million by 2034 , exhibiting a growth rate (CAGR) of 7.28 % during 2026-2034 . The market is driven by growing regulatory enforcement, increasing adverse drug reaction (ADR) reporting, expanding pharmaceutical industry, rising chronic disease prevalence, surging clinical trials, digital health integration, and heightened public awareness of drug safety.

MEXICO PHARMACOVIGILANCE MARKET TRENDS:

Strengthening Regulatory Frameworks and Compliance

The Mexico pharmacovigilance market share is expanding, due to the COFEPRIS and the National Pharmacovigilance Centre, as they have strengthened their regulatory systems. In line with this, the pharmaceutical sector follows requirements from COFEPRIS and the National Pharmacovigilance Centre to develop strict pharmacovigilance programs, which need continuous ADR reporting and risk management planning. Moreover, Mexico now applies real-time reporting technology because of regulatory updates that bring its standards closer to international pharmaceutical safety requirements. For example, in March 2024, COFEPRIS issued new Good Manufacturing Practice (GMP) guidelines, accepting certifications from regulatory agencies in Brazil, Argentina, Canada, and the U.S. This alignment with international standards aims to improve drug quality assurance and bolster pharmacovigilance practices. Besides this, the increased regulatory pressure makes pharmaceutical companies allocate funds to buy specialized resources and training programs. Furthermore, the post-market surveillance system, along with reporting efficiency, has significantly improved. Apart from this, the updated regulations are strengthening drug safety and creating confidence among stakeholders, which is increasing the investment in the pharmacovigilance system across the region.

Integration of Advanced Technologies in Pharmacovigilance

The Mexico pharmacovigilance market outlook is experiencing substantial changes because of the implementation of advanced technologies, including artificial intelligence (AI), machine learning (ML), and big data analytics. The combination of these technological tools improves ADR assessment by processing cases automatically and strengthening signal discovery abilities and boosting the decision-making process. Concurrently, the pharmaceutical industry now implements digital systems that obtain real-time information through electronic health records, along with mobile application data. For instance, in 2023, Mexico's regulatory authority, COFEPRIS, updated its Digital Research and Clinical Trials Platform (DIGIPRiS) to streamline the electronic submission and review of research protocols. This advancement aims to expedite approvals and improve the efficiency of pharmacovigilance activities by facilitating real-time data access and monitoring. In confluence with this, these changes enable precise drug risk assessment while fueling the detection of potential adverse events ahead of time, which minimizes dependence on traditional manual methods. Additionally, technology integration in pharmacovigilance operations leads to more operational effectiveness and improved patient safety results while streamlining modern pharmacovigilance processes. As a result, this trend is driving the Mexico pharmacovigilance market growth and positioning the region as a leading player in worldwide pharmacovigilance operations.

MEXICO PHARMACOVIGILANCE MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2026-2034. Our report has categorized the market based on service provider, product life cycle, type, process flow, therapeutic area and end use.

Service Provider Insights:

• In-house
• Contract Outsourcing

The report has provided a detailed breakup and analysis of the market based on the service provider. This includes in-house and contract outsourcing.

Product Life Cycle Insights:

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

A detailed breakup and analysis of the market based on the product life cycle have also been provided in the report. This includes pre-clinical, phase I, phase II, phase III, and phase IV.

Type Insights:

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

The report has provided a detailed breakup and analysis of the market based on the type. This includes spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining.

Process Flow Insights:

• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Reviewing and Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review and Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System

A detailed breakup and analysis of the market based on the process flow have also been provided in the report. This includes case data management (case logging, case data analysis, and medical reviewing and reporting), signal detection (adverse event logging, adverse event analysis, and adverse event review and reporting), and risk management system (risk evaluation system and risk mitigation system).

Therapeutic Area Insights:

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

The report has provided a detailed breakup and analysis of the market based on the therapeutic area. This includes oncology, neurology, cardiology, respiratory systems, and others.

End Use Insights:

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Companies
• Others

A detailed breakup and analysis of the market based on the end use have also been provided in the report. This includes pharmaceutical companies, biotechnology companies, medical device companies, and others.

Regional Insights:

• Northern Mexico
• Central Mexico
• Southern Mexico
• Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Mexico, Central Mexico, Southern Mexico, and others.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the Mexico pharmacovigilance market performed so far and how will it perform in the coming years?
• What is the breakup of the Mexico pharmacovigilance market on the basis of service provider?
• What is the breakup of the Mexico pharmacovigilance market on the basis of product life cycle?
• What is the breakup of the Mexico pharmacovigilance market on the basis of type?
• What is the breakup of the Mexico pharmacovigilance market on the basis of process flow?
• What is the breakup of the Mexico pharmacovigilance market on the basis of therapeutic area?
• What is the breakup of the Mexico pharmacovigilance market on the basis of end use?
• What is the breakup of the Mexico pharmacovigilance market on the basis of region?
• What are the various stages in the value chain of the Mexico pharmacovigilance market?
• What are the key driving factors and challenges in the Mexico pharmacovigilance?
• What is the structure of the Mexico pharmacovigilance market and who are the key players?
• What is the degree of competition in the Mexico pharmacovigilance market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MEXICO PHARMACOVIGILANCE MARKET - INTRODUCTION

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 MEXICO PHARMACOVIGILANCE MARKET LANDSCAPE

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 MEXICO PHARMACOVIGILANCE MARKET - BREAKUP BY SERVICE PROVIDER

6.1 In-house
  6.1.1 Overview
  6.1.2 Historical and Current Market Trends (2020-2025)
  6.1.3 Market Forecast (2026-2034)
6.2 Contract Outsourcing
  6.2.1 Overview
  6.2.2 Historical and Current Market Trends (2020-2025)
  6.2.3 Market Forecast (2026-2034)

7 MEXICO PHARMACOVIGILANCE MARKET - BREAKUP BY PRODUCT LIFE CYCLE

7.1 Pre-clinical
  7.1.1 Overview
  7.1.2 Historical and Current Market Trends (2020-2025)
  7.1.3 Market Forecast (2026-2034)
7.2 Phase I
  7.2.1 Overview
  7.2.2 Historical and Current Market Trends (2020-2025)
  7.2.3 Market Forecast (2026-2034)
7.3 Phase II
  7.3.1 Overview
  7.3.2 Historical and Current Market Trends (2020-2025)
  7.3.3 Market Forecast (2026-2034)
7.4 Phase III
  7.4.1 Overview
  7.4.2 Historical and Current Market Trends (2020-2025)
  7.4.3 Market Forecast (2026-2034)
7.5 Phase IV
  7.5.1 Overview
  7.5.2 Historical and Current Market Trends (2020-2025)
  7.5.3 Market Forecast (2026-2034)

8 MEXICO PHARMACOVIGILANCE MARKET - BREAKUP BY TYPE

8.1 Spontaneous Reporting
  8.1.1 Overview
  8.1.2 Historical and Current Market Trends (2020-2025)
  8.1.3 Market Forecast (2026-2034)
8.2 Intensified ADR Reporting
  8.2.1 Overview
  8.2.2 Historical and Current Market Trends (2020-2025)
  8.2.3 Market Forecast (2026-2034)
8.3 Targeted Spontaneous Reporting
  8.3.1 Overview
  8.3.2 Historical and Current Market Trends (2020-2025)
  8.3.3 Market Forecast (2026-2034)
8.4 Cohort Event Monitoring
  8.4.1 Overview
  8.4.2 Historical and Current Market Trends (2020-2025)
  8.4.3 Market Forecast (2026-2034)
8.5 EHR Mining
  8.5.1 Overview
  8.5.2 Historical and Current Market Trends (2020-2025)
  8.5.3 Market Forecast (2026-2034)

9 MEXICO PHARMACOVIGILANCE MARKET - BREAKUP BY PROCESS FLOW

9.1 Case Data Management
  9.1.1 Overview
  9.1.2 Historical and Current Market Trends (2020-2025)
  9.1.3 Market Segmentation
    9.1.3.1 Case Logging
    9.1.3.2 Case Data Analysis
    9.1.3.3 Medical Reviewing and Reporting
  9.1.4 Market Forecast (2026-2034)
9.2 Signal Detection
  9.2.1 Overview
  9.2.2 Historical and Current Market Trends (2020-2025)
  9.2.3 Market Segmentation
    9.2.3.1 Adverse Event Logging
    9.2.3.2 Adverse Event Analysis
    9.2.3.3 Adverse Event Review and Reporting
  9.2.4 Market Forecast (2026-2034)
9.3 Risk Management System
  9.3.1 Overview
  9.3.2 Historical and Current Market Trends (2020-2025)
  9.3.3 Market Segmentation
    9.3.3.1 Risk Evaluation System
    9.3.3.2 Risk Mitigation System
  9.3.4 Market Forecast (2026-2034)

10 MEXICO PHARMACOVIGILANCE MARKET - BREAKUP BY THERAPEUTIC AREA

10.1 Oncology
  10.1.1 Overview
  10.1.2 Historical and Current Market Trends (2020-2025)
  10.1.3 Market Forecast (2026-2034)
10.2 Neurology
  10.2.1 Overview
  10.2.2 Historical and Current Market Trends (2020-2025)
  10.2.3 Market Forecast (2026-2034)
10.3 Cardiology
  10.3.1 Overview
  10.3.2 Historical and Current Market Trends (2020-2025)
  10.3.3 Market Forecast (2026-2034)
10.4 Respiratory Systems
  10.4.1 Overview
  10.4.2 Historical and Current Market Trends (2020-2025)
  10.4.3 Market Forecast (2026-2034)
10.5 Others
  10.5.1 Historical and Current Market Trends (2020-2025)
  10.5.2 Market Forecast (2026-2034)

11 MEXICO PHARMACOVIGILANCE MARKET - BREAKUP BY END USE

11.1 Pharmaceuticals Companies
  11.1.1 Overview
  11.1.2 Historical and Current Market Trends (2020-2025)
  11.1.3 Market Forecast (2026-2034)
11.2 Biotechnology Companies
  11.2.1 Overview
  11.2.2 Historical and Current Market Trends (2020-2025)
  11.2.3 Market Forecast (2026-2034)
11.3 Medical Device Companies
  11.3.1 Overview
  11.3.2 Historical and Current Market Trends (2020-2025)
  11.3.3 Market Forecast (2026-2034)
11.4 Others
  11.4.1 Historical and Current Market Trends (2020-2025)
  11.4.2 Market Forecast (2026-2034)

12 MEXICO PHARMACOVIGILANCE MARKET – BREAKUP BY REGION

12.1 Northern Mexico
  12.1.1 Overview
  12.1.2 Historical and Current Market Trends (2020-2025)
  12.1.3 Market Breakup by Service Provider
  12.1.4 Market Breakup by Product Life Cycle
  12.1.5 Market Breakup by Type
  12.1.6 Market Breakup by Process Flow
  12.1.7 Market Breakup by Therapeutic Area
  12.1.8 Market Breakup by End Use
  12.1.9 Key Players
  12.1.10 Market Forecast (2026-2034)
12.2 Central Mexico
  12.2.1 Overview
  12.2.2 Historical and Current Market Trends (2020-2025)
  12.2.3 Market Breakup by Service Provider
  12.2.4 Market Breakup by Product Life Cycle
  12.2.5 Market Breakup by Type
  12.2.6 Market Breakup by Process Flow
  12.2.7 Market Breakup by Therapeutic Area
  12.2.8 Market Breakup by End Use
  12.2.9 Key Players
  12.2.10 Market Forecast (2026-2034)
12.3 Southern Mexico
  12.3.1 Overview
  12.3.2 Historical and Current Market Trends (2020-2025)
  12.3.3 Market Breakup by Service Provider
  12.3.4 Market Breakup by Product Life Cycle
  12.3.5 Market Breakup by Type
  12.3.6 Market Breakup by Process Flow
  12.3.7 Market Breakup by Therapeutic Area
  12.3.8 Market Breakup by End Use
  12.3.9 Key Players
  12.3.10 Market Forecast (2026-2034)
12.4 Others
  12.4.1 Historical and Current Market Trends (2020-2025)
  12.4.2 Market Forecast (2026-2034)

13 MEXICO PHARMACOVIGILANCE MARKET – COMPETITIVE LANDSCAPE

13.1 Overview
13.2 Market Structure
13.3 Market Player Positioning
13.4 Top Winning Strategies
13.5 Competitive Dashboard
13.6 Company Evaluation Quadrant

14 PROFILES OF KEY PLAYERS

14.1 Company A
  14.1.1 Business Overview
  14.1.2 Services Offered
  14.1.3 Business Strategies
  14.1.4 SWOT Analysis
  14.1.5 Major News and Events
14.2 Company B
  14.2.1 Business Overview
  14.2.2 Services Offered
  14.2.3 Business Strategies
  14.2.4 SWOT Analysis
  14.2.5 Major News and Events
14.3 Company C
  14.3.1 Business Overview
  14.3.2 Services Offered
  14.3.3 Business Strategies
  14.3.4 SWOT Analysis
  14.3.5 Major News and Events
14.4 Company D
  14.4.1 Business Overview
  14.4.2 Services Offered
  14.4.3 Business Strategies
  14.4.4 SWOT Analysis
  14.4.5 Major News and Events
14.5 Company E
  14.5.1 Business Overview
  14.5.2 Services Offered
  14.5.3 Business Strategies
  14.5.4 SWOT Analysis
  14.5.5 Major News and Events

15 MEXICO PHARMACOVIGILANCE MARKET - INDUSTRY ANALYSIS

15.1 Drivers, Restraints, and Opportunities
  15.1.1 Overview
  15.1.2 Drivers
  15.1.3 Restraints
  15.1.4 Opportunities
15.2 Porters Five Forces Analysis
  15.2.1 Overview
  15.2.2 Bargaining Power of Buyers
  15.2.3 Bargaining Power of Suppliers
  15.2.4 Degree of Competition
  15.2.5 Threat of New Entrants
  15.2.6 Threat of Substitutes
15.3 Value Chain Analysis

16 APPENDIX